# Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation

> **NCT04838704** · NA · COMPLETED · sponsor: **Zhejiang University** · enrollment: 215 (actual)

## Conditions studied

- Graft Versus Host Disease

## Interventions

- **DRUG:** Ruxolitinib+Calcineurin inhibitor+Methotrexate
- **DRUG:** Calcineurin Inhibitor+Methotrexate+Mycophenolate mofetil

## Key facts

- **NCT ID:** NCT04838704
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2025-06-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04838704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04838704, "Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04838704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*